TABLE 2.
Drug(s)/name | Screening technique | Target protein | No. of drugs | Data Bank | Refs. |
---|---|---|---|---|---|
Carfilzomib, Eravacycline, Valrubicin, Lopinavir, and Elbasvir | Docking | Mpro | 2201 | DrugBank | Wang (2020) |
Paritaprevir, Simeprevir, Ledipasvir, Glycyrrhizic acid, TMC‐310911 | Docking | 3CLpro, PLpro, cleavage site, HR1 and RBD | 2471 |
Protein data bank Drugbank |
Mahdian et al. (2020) |
Binifibrate, bamifylline, rilmazafon, afatinib, ezetimibe, macimorelin, and acetate | E‐pharmacophore based virtual screening, structure based virtual screening | 3CLpro | 4600 | SuperDRUG2 database | Arun et al. (2021) |
Sovaprevir, Danoprevir, Samatasvir, Ritonavir, Rebamipide, Zabofloxacin, Pralatrexate, … | Docking | Mpro, PLpro, and the S‐protein | 11,552 |
Protein data bank Drugbank, ChEMBL DrugCentral database of approved drugs, Selleck Chemicals library |
Cavasotto and Di Filippo (2021) |
Melatonin, Mercaptopurine, Sirolimus | Network‐based | Membrane (M), spike (S), nucleocapsid (N) proteins envelope (E), and Replicase complex (ORF1ab) nucleocapsid proteins | 2000 | DrugBank Database (TTD), PharmGKB, ChEMBL, BindingDB89, and IUPHAR/BPS Guide Pharmacology | Zhou et al. (2020) |
Penciclovir, Ribavirin, and Zanamivir | Docking | Spike protein, isolate spike protein RBD, NSP 10, NSP 16, main protease, and RdRp polymerase | 48 | FDA and SUS databanks | Grahl et al. (2021) |
Drug(s)/Name | Computation | Target protein | No. of drugs | Data Bank | Refs. |
---|---|---|---|---|---|
Paromomycin Phensuximide Magnesium ascorbate Tizanidine Cefotiam Voriconazole, Tobramycin Kanamycin, |
Docking | Mpro | 1490 |
UniProt Drugbank |
Sencanski et al. (2020) |
Lopinavir, Asunaprevir, Indinavir, Ritonavir, Remdesivir, Methisazone Paritaprevir |
Docking |
Protease inhibitor Inhibits viral DNA polymerase Protease inhibitor HIV protease inhibitor Viral RNA polymerase Inhibits mRNA and protein synthesis Inhibitor of the nonstructural protein 3‐4A (NS3/4A) serine protease |
61 |
PubChem database Protein Data Bank (http:// www.rscb.org) |
Shah et al. (2020) |
Talampicillin, Lurasidone, Rubitecan and Loprazolam Talampicillin, Lurasidone, ZINC000015988935, ZINC000103558522 (drug‐like molecules) |
Docking | Mpro and TMPRSS2 enzymes |
4500 30,000 (drug‐like molecules) |
ChEMBL, DrugBank and Selleckchem ZINC15 database |
Elmezayen et al. (2020) |
Darunavir, Nelfinavir and Saquinavir |
(MOE) Docking Molecular Operating Environment |
Mpro | >2000 | drugbank.ca | Farag et al. (2020) |
Remdesivir, Saquinavir and Darunavir Small molecules: flavone and coumarin derivatives |
(MOE) Docking Molecular dynamics simulation |
3CLpro | 16 |
in‐house database RCSB Protein Data Bank |
Khan et al. (2020) |
Ritonavir |
Docking Molecular dynamics simulation |
Mpro | 18 | Drug Bank | Ibrahim et al. (2021) |
Paritaprevir, Semeprevir, Grazoprevir Velpatasvir |
Docking Supervised machine learning |
Spike protein, nucleocapsid protein, and 2′‐o‐ribose methyltransferase | 1577 | ZINC database | Kadioglu et al. (2020) |